Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5857494 | 0.89 | HPGDS (0.33) | ALDH1A1HPGDSGSK3BCYP2C9CYP2C19 | |
| SCHEMBL16753610 | 0.77 | DAO (0.47) | ALDH1A1HPGDSGSK3B | |
| SCHEMBL5857383 | 0.77 | GSK3B (0.51) | ALDH1A1HPGDSGSK3BNPSR1 | |
| SCHEMBL15057163 | 0.76 | CA12 (0.39) | ALDH1A1GSK3B | |
| SCHEMBL5857434 | 0.76 | CA12 (0.45) | ALDH1A1CYP2C19 | |
| SCHEMBL18152995 | 0.74 | GSK3B (0.44) | ALDH1A1HPGDSGSK3BNPSR1 | |
| SCHEMBL15079197 | 0.72 | GSK3B (0.42) | ALDH1A1HPGDSGSK3B | |
| SCHEMBL18152997 | 0.71 | GSK3B (0.33) | ALDH1A1HPGDSGSK3BCYP2C9 | |
| SCHEMBL5856640 | 0.71 | MAPT (0.44) | ALDH1A1HPGDSGSK3BNPSR1 | |
| SCHEMBL1753907 | 0.71 | CES2 (0.53) | ALDH1A1HPGDSGSK3BNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115595-B2 | Carbapenem compounds | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2006-10-03 | — | — | US | disclosed |
| EP-1357123-B1 | Novel carbapenem, medical and antibacterial comprisisng the same, and uses thereof | SUMITOMO PHARMA (JP) | 2005-11-30 | — | — | EP | disclosed |
| EP-1535924-A1 | Novel carbapenem compounds | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-06-01 | — | — | EP | disclosed |
| US-20040063683-A1 | Novel carbapenem compounds | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1357123-A1 | NOVEL CARBAPENEM COMPOUNDS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063683-A1 | Novel carbapenem compounds | PTMS, PNISR, LRPPRC | ALDH1A1 2608/4885HPGDS 456/4885GSK3B 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.